MUCOSAL IgA IS THE NEXT FRONTIER OF IMMUNITY.
Lactiga™ is an award-winning, venture-backed biotechnology company developing innovative mucosal antibody therapies to advance the future of immunoscience. We are unlocking the full therapeutic value of human milk to create the world’s first platform for secretory IgA antibodies. Our groundbreaking approach has the potential to transform treatment for conditions like chronic respiratory disorders, gut inflammation, immune deficiencies, and more, positioning us at the forefront of immunotherapy innovation.
LEVERAGING NATURE TO ELEVATE IMMUNITY
Secretory Immunoglobulin A (sIgA) is a key antibody found in mucosal surfaces throughout the body, including the respiratory, digestive, and ocular compartments. Our first-in-class sIgA therapeutic has the potential to enhance mucosal immunity across conditions affecting these regions.
UNLOCKING THE THERAPEUTIC POWER OF HUMAN MILK ANTIBODIES
At Lactiga, we are harnessing the power of maternal antibodies naturally found in breastmilk to develop biologics that can help dysregulated immune systems in patients of all ages.
MEDIA & INVESTORS
-
PODCASTS
-
IN THE NEWS
-
AWARDS & ANNOUNCEMENTS
"This is the start of Lactiga's ambitious mission to shift the paradigm of therapeutic antibody development from systemic to mucosal delivery, where many pathogens initially enter the body. By targeting the mucosal immune system, we can create more effective therapies that prevent infection at the point of entry, leading to a much better quality of life, especially in our most vulnerable populations."
- Dr. Rikin Mehta, Lactiga Co-founder and CEO
